MARKET

XRTX

XRTX

Xortx Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.430
-0.040
-2.72%
Opening 15:17 05/19 EDT
OPEN
1.460
PREV CLOSE
1.470
HIGH
1.460
LOW
1.391
VOLUME
24.87K
TURNOVER
30.91K
52 WEEK HIGH
8.19
52 WEEK LOW
0.9600
MARKET CAP
18.58M
P/E (TTM)
-10.7681
1D
5D
1M
3M
1Y
5Y
AxoGen, Better Therapeutics top healthcare gainers; Nephros, BioAtla lead losers' pack
Gainers: AxoGen (AXGN) +26%. Better Therapeutics (BTTX) +15%. Intercept Pharmaceuticals (ICPT) +13%. XORTX Therapeutics (XRTX)  +13%. Belite Bio (BLTE) +8%. Losers: Nephros (NEPH) -32%. BioAtla (BCAB) -27%. Outset Medical (OM) -10%. Signify Health (SGFY) -...
Seekingalpha · 05/05 14:02
BRIEF-XORTX Opens An Ind For Xrx-008 Program For Autosomal Dominant Polycystic Kidney Disease
reuters.com · 05/05 11:26
XORTX Opens An IND For XRx-008 Program For Autosomal Dominant Polycystic Kidney Disease
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a clinical stage pharmaceutical company focused on developing innovative therapies to treat progressive
Benzinga · 05/05 11:09
XORTX Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease
● FDA Provides All Clear Notification for IND and Bridging Pharmacokinetics Study ● CALGARY, Alberta, May 05, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical stage pharmac...
GlobeNewswire · 05/05 11:00
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday.
Benzinga · 05/04 17:45
27 Stocks Moving in Wednesday's Pre-Market Session
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares rose 38.5% to $1.87 in pre-market trading after gaining around 5% on Tuesday.
Benzinga · 05/04 10:26
ATNF, CYN and BWV among mid-day movers
Gainers: Sonoma Pharmaceuticals (SNOA) +29%. Blue Water Vaccines (BWV) +32%. XORTX Therapeutics (XRTX) +27%. Eqonex  (EQOS) +21%. TETRA Technologies (TTI) +20%. Enovix (ENVX) +18%. JAKKS Pacific (JAKK) +18%. Blue Apron
Seekingalpha · 05/03 16:53
Sonoma, XORTX top healthcare gainers; Spero, Semler Scientific lead losers' pack
Gainers: Sonoma Pharmaceuticals (SNOA) +42%. XORTX Therapeutics (XRTX) +18%. Retractable Technologies (RVP) +14%. Catalent (CTLT) +12%. Field Trip Health (FTRP) +5%. Losers: Spero Therapeutics (SPRO) -61%. Semler Scientific (SMLR) -23%. Galmed Pharmaceutic...
Seekingalpha · 05/03 14:04
More
No Data
Learn about the latest financial forecast of XRTX. Analyze the recent business situations of Xortx Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.50%
Pharmaceuticals & Medical Research
+0.35%
Key Executives
Non-Executive Chairman/Independent Director
Bruce Rowlands
President/Chief Executive Officer/Director
Allen Davidoff
Chief Financial Officer
Amar Keshri
Chief Technology Officer
David MacDonald
Other
Stephen Haworth
Other
Brian Mangal
Other
Alan Moore
Director
Raymond Pratt
Independent Director
William Farley
Independent Director
Ian Klassen
Independent Director
Jacqueline Le Saux
Independent Director
Paul Van Damme
No Data
No Data
About XRTX
XORTX Therapeutics Inc. is a Canada-based pharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) due to coronavirus infection. Its lead product candidates are XRx-008, XRx-101 and XRx-225. XRx-008 is a late clinical stage program focused on demonstrating the potential of its therapy for ADPKD. XRx-101 is a program to treat acute kidney injury associated with Coronavirus/ COVID-19 infection, AKI and associated health consequences. XRx-225 is a program for the treatment of T2DN. It is also working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.

Webull offers kinds of XORTX Therapeutics Inc stock information, including NASDAQ:XRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XRTX stock methods without spending real money on the virtual paper trading platform.